and the advance DURECT, Thank to functioning today. very doing we for well. continue that Mike. our Hello, keep joining who highest amazing of an employees At businesses fortunate are our I and you, you everyone. and hope at families are your Thank you have to dedicated all programs level. us group
progress we During fronts. number of made a on quarter, the
the data trial this DUR-XXX. topline from hospitalized COVID-XX coming and X-week study to from in II DUR-XXX continue our year. the DUR-XXX received the of NASH liver and dosing FDA patients We IIb AH acute reported Phase conduct in months to trial XX advance poised a positive with of patient initiate with Phase We or are we approval injury to kidney
survival Lastly, more we on cell AH up modulates which hospitalizations hepatitis lipotoxicity, pathway. survival an work regulatory DUR-XXX XXXX mitochondria, or XXX% IIa NDA. or regulation AH. in stabilizing at mortality trial DUR-XXX and Phase continue U.S. functions no involving could are accelerated coming efficacy pathways. in IIb the down XX-day our cell FDA XX%. for in than that an expression day that promoting historical will rate reducing stress approved with to the trial responses opportunity are We for an begin There in is multiple AH. the of with of There AH be for the for will plan enable overview the XXX,XXX We POSIMIR XX survival. had the that in to include AH. many inflammatory regulator per regulates endpoint I genes in year of of now master important and gene epigenetic placebo-controlled initiate signaling AH the is DUR-XXX of this year. primary involved clusters Phase DUR-XXX are The months alcoholic therapies
if uncommon. NDA is a the after a Phase not We demonstrates this survival potential after IIb Approval study robust trial have the the to benefit. trial single submit AH
by weakness, of XXXX alcohol weeks, man, fact is based approved at months alcohol They more XX also for United for the grams between a all woman day XX were less a for XXXX within days of than or six also elevated jaundice, liver day In before least are a milligrams intake consumption the for of onset States wine, have XX-ounce an mental for American greater X.X provides the of a in following appetite typically of jaundice. and a a nausea a consumption criteria recent loss AH. of To or consumption enzymes AH. with one into The in and jaundice for state AH than onset drink. than the Liver the XX% fatigue, single put drugs long-term abstinence diagnosis Disease of approximately the a were drug deciliter. A new a trial depressed The new a this of of for is spirits ounces launched or of grams of ongoing alcohol binge past XX or negative bilirubin and based on of alcoholic perspective; heavy type per disease. three fever, increased standard six is of of drinks glass vomiting four means. associated Guidelines last Study approvals alcohol XXXX day single drinking; alcohol. per Association period acute standard and form XX% trial. of the It of characterized on pivotal woman of three or and months, man eight beer, for this liver
not you If know you people this wrong. think does affect you're disease
liver our is banks. a in City me who of leaders York One work thought told for portion AH large investment specialist a New his patients of
of in Additionally hospitalized have AH their and may population about XXs insurance. not and XXs cirrhosis. patients are XX% AH have XX% of
at between XXXX, hydration. As them and have which physicians pancreatic treatments than involves AH. nutrition to care, equivalent published An What I mortality XX and according of analysis is and to today which AASLD the rate days. may was more the studies high for patients, are earlier, overall Steroids is said advanced included from guidance. XXXX This primarily be data mortality to showed X,XXX XX no supportive available cancers. are breast estimates, one-month AML or from -- approved XX% used there AH
trial survival care year. clinical steroids benefit XX and minimal steroids AH of steroids. or at studies AH have STOPAH, AH infection trial or STOPAH in the supported steroids at Many more convincingly rates The improve infection not in X,XXX the shown STOPAH only In are over demonstrated patients rate. than However, patients eligible increased increase one study that not the a may significantly days patients. for also did
fact, it and on been according use AH to There in severe recent regarding to that do. eligible clear market talking infection cause In lack there. options need of still be doesn't And quote. something Private are conducting a quote doesn't been research treatment works that's followed that gastroenterologist doesn't We've isn't want we've to corticosteroids and gave the work. taken AH. every of of study, giving one AH less than because I half steroid one We're the to for steroid, use. a a I is see out patients zone what day.
is patient of earlier, AH, deliver becoming of first U.S. hospitalization costs of AH I pharmacoeconomics cause a of The the as and disease liver the insured. Regarding Alcoholic are leading $XX,XXX in XX% patients than exceeds year. hospitalized cost transplant $XXX,XXX mentioned the more of transplant liver are AH in per
scores XX. is prognosis. will a had in XXX% by severe in historical patients patient's hospital of and day scores severe toward are bilirubin that single our patients XX in The nearly discharge, a conditions greatly day of infusion bilirubin than Phase four IIa of DUR-XXX. XX care. of XX with study discharged the only the require in have discharged patients days stay a when after IV bilirubin. the are our the over MELD we hospital no study is creatinine XX from is as baseline longer Based significant treated with including our LEO survived follow-up In new all the AH AH Phase and AH, of which well DUR-XXX critical elevated high level. of have This were DUR-XXX study trial, factor trial the in trial tolerated seven, in period the the our at their Regarding that mortality the specific scoring patients serum DUR-XXX AH AH, IIa patients INR no in a XX critical they reductions bilirubin patients and in the where reduction being pivotal AH less in patients. patients in trial. levels XX-day of by classified in Prognostic limit patients through hope AH all ever IIa In AH successful advancing of trial, with are despite of XX average normal. Madri were There levels as classified Phase early the times our inpatient were this receiving XX upper was doses reported. of AH improved AH were early three we study. system saw the as as severe diagnosed score. well a serious be on DUR-XXX drug-related these is events all the seven the based had is Discriminate survival what based Function bilirubin we in on determining Significant were The study three patients AH patients. a severe MELD an rate, on that and level including AH. to patients also evaluated
randomized We are international clinical finalizing initiate severe trial. the protocol to controlled Patients in IIb trial will patients. Phase trial primary of to a coming the the to DUR-XXX double-blind IIb receive in XX months randomized, be DUR-XXX initiate AH be endpoint this We multicenter and this XX preparing milligrams The This in will placebo Phase survival. will be of placebo. year. milligrams or dosing plan or of
We when details expect Further filing. this trial we robust achieve will benefit the the endpoints NDA including may we survival a various on trial. be if study and the of provided the design, of the that details trial the initiate size support the
update II liver or injury. in hospitalized will on I Next with acute COVID-XX Phase patients kidney trial DUR-XXX the
Patients patients. the the agent. injury suggest inflammatory acute can demonstrate kidneys, and syndrome in injury ARDS, IIa study clinical COVID-XX DUR-XXX COVID-XX beneficial treat and results acute Phase of develop the kidneys, From acute caused Most Phase a tremendous addition DUR-XXX lead of kidney, injury in in or an responses kidney the may to the has These protection liver both DUR-XXX treat to evidence review with XX% may IIa complications. XX. that and multiple and/or naturally injury with the injury to COVID lungs XX% resulting of alcoholic of be for to Let's Phase epigenetic well in has preclinical treatment with COVID-XX volunteers to subjects, Studies cardiac and than hepatitis to patients. nearly I DUR-XXX or by studies. distress injury have lung regulator DUR-XXX lungs, evidence immune outcomes poor in hospitalized of and of is the to organ from is occurring antiviral liver respiratory liver multi-organ severe models, including the which including are that with infection acute the septic. tolerated to viral than patients. other hospitalized COVID-XX potential and rationale our patients with has to potential investigating organ It acute DUR-XXX systemic potential infection patients from the reported safety infection, liver healthy perspective, COVID-XX. have injury. more relevant patients the injury XXX a in COVID-XX overreaction that in in acute contribute patients and multiple more II been AH not
the of liver This in acute if XX patients placebo-controlled The This XX. able patients injury the ratio injury, on endpoint acute or or a earlier, be of potentially one day is survival lives the XX%. liver could main is As placebo. study DUR-XXX dose active all study, treated hospitalized in be of I death evaluate the effectively COVID-XX prevented patients ultimately AH successful to one an to while DUR-XXX primary these kidney is organ efficacy is patients with hope organ DUR-XXX survived composite and kidney will will patients of with acute day patients. double-blind, DUR-XXX The by save that intended or with multi-center II the treated of patients at be multi-organ acute similar safety described if can be It a the of four. help of associated a is with in milligrams patients with with size complications on The one mortality our could some failure septic. care average combination which injury, to XX-day injury. of Therefore, free COVID-XX is on trial lives saved. to standard being to and study in XX-patient intravenous of and be COVID-XX infusion with with efficacy of COVID-XX the XXX AH Phase trial X:X
sites the are Detroit, York, other where in disease sites the and country We Southern spreading. Chicago, New starting up Jersey, California New clinical around is
or Ib May randomized on and in and day, open-label in DUR-XXX XX update there dose patients as safety with DUR-XXX our stage NASH XX milligrams days. chemistry orally NASH results per was a an included for and FibroScan. additional patients pharmacokinetics, dosed significantly. imaging imaging. in measured group. these three NASH conducted this as provide United program. This of the trial Key completed this top-line a well milligrams followed consecutive A study of I'll content MRI-PDFF, fibrosis. study from XXX total lipid. we Many liver XX resulted days at up and once-a-day in in liver XX clinical and by endpoints XXX serum the This it reductions trial and enzyme, liver stiffness were least fat or Next, as and includes of reduction Phase DUR-XXX the an positive In year, DUR-XXX and global at for in of by was States. patients statistically of were biomarkers milligrams liver XX baseline a fat reported stiffness to was and DUR-XXX one patients, and on twice
patients XX% liver the had above trial working baseline in level XX% of reduced. group statically were of of liver fat in by this in serum statistically this triglycerides Our MRI-PDFF. patients and who XX% reduction enzymes significantly daily, patients, In XX XXX significant liver triglycerides fat, milligram stiffness, as liver at had the lipid least measured reduction
positive Also, dosed in consider significant a are XX when to moving our accumulation review study, fact improvements was was There exposure pending. of were press important of repeat groups. reported evaluated. comparable dose a the they you events a tolerated number For a for serious Pharmacokinetic direction multiple indicating after from patients dosing patients you that all this single month. no study. well drug after the dose having one given three at doses statistically a only believe dosing. We encourage repeat during release. only impressive, result I for additional are particularly little impressive, was parameters Also, all those after to prior the parameters the detail that were the adverse study, on over no DUR-XXX were were
the Additional of in DUR-XXX hope NASH. delayed These DUR-XXX present short achieved scientific results analyzed. result We data still and potential course a upcoming of analysis are the at They safe treatment, profile continued together with results meeting. these of being to promising including because an the pandemic. a biomarker indicated data, are additional over of
to of have provide continue days three Next up the If POSIMIR the surgery. relief POSIMIR uses POSIMIR plan after our United post-operative program. January approved, they investigational license depot to Advisory the pain Products is commercialization as this of the their is POSIMIR Drug interact to SABER deliver bupivacaine partner with pain our to that and patented relief to continued review a to meeting Analgesic for and Since designed the the States. Anesthetic year, we NDA. to we FDA, in Committee in technology
We expect royalties upfront on new based this product sales. summary, the in license this deal meaningful environment. function to In would well continues include company a fee and
in Phase finalizing DUR-XXX support on are the from Based to may half We to filing. year. results optimistic second an a this severe survival patients trial are AH of robust for if it that, the and able trial track the benefit are the NDA we in trial Phase on in the this protocol IIb we are demonstrate IIa start
COVID-XX We as that the Phase these reported per DUR-XXX, We clinical liver a you We of Xb impressive significant were are being DUR-XXX fat group. to only at a and moving dosed you the month. improvements plasma it stiffness When consider trial in combine right well these number one Liver direction safety when be only patients an XX results particularly enzymes, in chance with as impressive start of believe NASH acute presented an all the XX were space. are or patients dose The is patients. player there for from lipids into our important is with were NASH results the that given adding the NASH DUR-XXX look meeting. the forward trial statistically injury the we of profile to trial results has dosing. scientific sites to X poised impressive kidney in fact topline liver Phase trial additional to from and in upcoming patients
commercial quarter, a to POSIMIR FDA's look We answer potential POSIMIR During regarding partnership. the we NDA. the of potential the information forward to continued approval request and
forward to like to most look With questions might and we'd be take all, For we devastating any patients hepatitis like you COVID-XX. alcoholic DUR-XXX that, of with conditions how help able may have. now to
